<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393116</url>
  </required_header>
  <id_info>
    <org_study_id>CAN-17-02</org_study_id>
    <nct_id>NCT04393116</nct_id>
  </id_info>
  <brief_title>Patients' Guidance With Onco-Coaching and CANKADO on Systemic Chemotherapy for Metastatic Colorectal Cancer</brief_title>
  <acronym>POSCA</acronym>
  <official_title>Patients' Guidance With Onco-Coaching and CANKADO on Systemic Chemotherapy for Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cankado Service GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cankado Service GmbH</source>
  <brief_summary>
    <textblock>
      This is a prospective, single arm, non-interventional project to evaluate the&#xD;
      benefit/influence of individualized patient education and guidance with a web-based e-Health&#xD;
      platform called CANKADO on patient reported outcomes (PRO) for patients with metastatic&#xD;
      colorectal cancer. The focus will be on patient reported outcomes (PRO), distress, Quality of&#xD;
      Life (QoL), Global Health Status, complaints and therapy relevant decisions. All patients&#xD;
      will be medically treated according to the standards. The experimental arm will include 40&#xD;
      patients. Those patients will receive one initial coaching before start of therapy. Further&#xD;
      appointments for coaching will be scheduled depending on individual patient's need. During&#xD;
      treatment period the patient is encouraged of joining therapy actively documenting his state&#xD;
      of health and occurring health complaints via CANKADO to give the physician a better overview&#xD;
      on the process of patient's health behaviour and preparing him for the next doctor-patient&#xD;
      consultation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of patients' Distress</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated using the Screening Tool for Measuring Distress described by the Practice Guidelines in Oncology - v. 1.2005 by the National Comprehensive Cancer Network</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's Quality of Life (QoL)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated using the EORTC QLQ-C30, which is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials. The five functional scales, three symptom scales, one global health status / QoL scale, and six single items are calculated according to the scording procedures defined by the QL Coordinator, Quality of Life Unit, EORTC Data Center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global health status</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated using the EQ visual analogue scale (EQ-VAS Scale), a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' (maximum value = 100) and 'The worst health you can imagine' (minimum value = 0).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with metastatic colorectal cancer in first line treatment treated in&#xD;
        &quot;Gemeinschaftspraxis für Hämatologie und Onkologie Langen&quot; or &quot;Hämato-Onkologische&#xD;
        Schwerpunktpraxis am Klinikum Aschaffenburg&quot;&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minumum age of 18 years&#xD;
&#xD;
          -  Patient with metastatic colorectal cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timo Schinköthe, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cankado Service GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lena-Sophie Fink</last_name>
    <phone>+4922142915300</phone>
    <email>l.fink@cankado.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hämato-onkologischer Studienkreis am Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Langen</city>
        <zip>63225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

